April 2026
M	T	W	T	F	S	S
	1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30

David Ferreira: Identifying the True Drivers of Recurrent Thrombosis

David Ferreira/LinkedIn

Apr 23, 2026, 08:16

David Ferreira: Identifying the True Drivers of Recurrent Thrombosis

David Ferreira, Director of the Immuno-hemotherapy Service at ULSGE at Gaia and Espinho Local Health Unit, shared a post on LinkedIn:

“Therapeutic anti-Xa.

INR on target.

DOAC in the right dose — and taken.

And yet… new thrombosis.

What now?

Increase hypocoagulation?

Change drugs?

Or stop for 30 seconds to think?

There is a pattern that repeats itself — and is rarely questioned: thrombosis patient – correct hypocoagulation – new thrombosis – escalate or change hypocoagulation.

Three very real examples:

Sepsis. Activated endothelium, systemic inflammation.
Will it solve with more hypocoagulation?
Lupus Flare/ Immune system in overdrive.
Will it solve with more hypocoagulation?
Catastrophic antiphospholipid syndrome (or similar phenotype). Cascading microthrombosis, consumption.
Will it solve with more hypocoagulation?

The problem is not hypoglutilation.

It is the reasoning. We increased doses. We changed drugs.

Because these patients are not thrombosing due to ‘lack of anticoagulant.’

They are thrombosing because:

Activated endothelium
High tissue factor
NETs
blocked fibrinolysis

In a word – Thrombo-Inflammation!

The system is thus mandatorily programmed to thrombo.

And how do we respond?

More hypocoagulation, hypocoagulant exchange.

This is not therapeutic failure.

It is conceptual failure.

The right question is not ‘What’s the next hypocoagulant?’, but ‘What is fueling this thrombosis?’

And in practice, what changes?

Confirm that you are well hypocoagulated.

Search for the driver.

And then act where it matters:

Sepsis/infection – aggressive focus control
Active autoimmune disease – immunosuppression (e.g., corticosteroids) plus/minus targeted therapy
Severe antiphospholipid syndrome – combined approach (hypocoagulation plus immune modulation depending on context)
Active neoplasm – treat the underlying disease
Arterial/platelet phenotype – consider antiplatelet therapy (e.g., clopidogrel) in an appropriate context

Hypocoagulation continues.

But it is no longer the center of the strategy.

Because the reality is this:

Hypocoagulation treats the thrombus.

But who decides the outcome… it is inflammation.

If this bothers you, great.

It’s supposed.

At the end of the day, the most important thing about auscultation is not the stethoscope.

It is between the ears of those who wear it.”

David Ferreira: Identifying the True Drivers of Recurrent Thrombosis